BRPI0510697A - gm3 sintase como um alvo terapêutico em complicações micro-vasculares da diabete - Google Patents

gm3 sintase como um alvo terapêutico em complicações micro-vasculares da diabete

Info

Publication number
BRPI0510697A
BRPI0510697A BRPI0510697-4A BRPI0510697A BRPI0510697A BR PI0510697 A BRPI0510697 A BR PI0510697A BR PI0510697 A BRPI0510697 A BR PI0510697A BR PI0510697 A BRPI0510697 A BR PI0510697A
Authority
BR
Brazil
Prior art keywords
diabetes
synthase
micro
therapeutic target
vascular complications
Prior art date
Application number
BRPI0510697-4A
Other languages
English (en)
Inventor
Samer Elbawab
Elodie Masson
Daniel Ruggiero
Nicolas Wiernsperger
Michel Lagarde
Lysiane Troncy
Original Assignee
Merck Patent Ges Mit Berschron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0404971A external-priority patent/FR2869915B1/fr
Application filed by Merck Patent Ges Mit Berschron filed Critical Merck Patent Ges Mit Berschron
Publication of BRPI0510697A publication Critical patent/BRPI0510697A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

GM3 SINTASE COMO UM ALVO TERAPêUTICO EM COMPLICAçõES MICROVASCULARES DA DIABETE. A presente invenção refere-se ao uso de um inibidor da expressão ou atividade do gene de GM3 síntase para o tratamento de complicações microvasculares da diabete, e a um método de triar os compostos úteis no tratamento e/ou prevenção destas complicações.
BRPI0510697-4A 2004-05-07 2005-04-07 gm3 sintase como um alvo terapêutico em complicações micro-vasculares da diabete BRPI0510697A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0404971A FR2869915B1 (fr) 2004-05-07 2004-05-07 Gm3 synthase, comme cible therapeutique dans les complications microvasculaires du diabete
FR0413530 2004-12-17
PCT/EP2005/003647 WO2005108600A1 (en) 2004-05-07 2005-04-07 Gm3 synthase as a therapeutic target in microvascular complications of diabetes

Publications (1)

Publication Number Publication Date
BRPI0510697A true BRPI0510697A (pt) 2007-12-26

Family

ID=34979036

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510697-4A BRPI0510697A (pt) 2004-05-07 2005-04-07 gm3 sintase como um alvo terapêutico em complicações micro-vasculares da diabete

Country Status (12)

Country Link
US (1) US20070224200A1 (pt)
EP (1) EP1743033B1 (pt)
JP (1) JP4921357B2 (pt)
KR (1) KR20070007908A (pt)
AT (1) ATE529531T1 (pt)
AU (1) AU2005240714B2 (pt)
BR (1) BRPI0510697A (pt)
CA (1) CA2565676C (pt)
ES (1) ES2375626T3 (pt)
MX (1) MXPA06012690A (pt)
RU (1) RU2006143156A (pt)
WO (1) WO2005108600A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161586A1 (en) * 2004-01-16 2007-07-12 Takeda Pharmaceutical Company Limited Drug for preventing and treating atherosclerosis
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
KR100734928B1 (ko) 2006-02-16 2007-07-03 한국생명공학연구원 갱글리오사이드 ＧＭ3 합성효소를 저해하는 ｓｉ핵산 및 그서열
SI2032134T1 (sl) 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
US8465930B2 (en) 2006-05-30 2013-06-18 Japan Science And Technology Agency Method for detection of disease having insulin-resistant conditions
EP2594564B1 (en) 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
MX337396B (es) 2007-10-05 2016-03-02 Genzyme Corp Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica.
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN107935983A (zh) 2008-10-03 2018-04-20 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合酶抑制剂
CA2741664C (en) * 2008-10-31 2014-12-23 Japan Science And Technology Agency Method for selective control of helper t cell function
US20100248365A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
ES2581523T3 (es) 2009-09-01 2016-09-06 Lz Therapeutics, Inc. Producción en cultivo celular (no bovino, no porcino) de GM1
JP5077901B2 (ja) * 2009-11-27 2012-11-21 独立行政法人科学技術振興機構 高脂血症治療剤のスクリーニング方法
WO2011133918A1 (en) * 2010-04-23 2011-10-27 Isis Pharmaceuticals, Inc. Modulation of gm3 synthase (gm3s) expression
WO2011146804A2 (en) * 2010-05-20 2011-11-24 Lazarus Therapeutics, Inc. Gm3 ganglioside replacement therapy
US20130040953A1 (en) * 2011-08-10 2013-02-14 Amy S. Paller Promotion of wound healing
US9556467B2 (en) 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2019082912A1 (ja) * 2017-10-27 2019-05-02 学校法人北里研究所 慢性腎臓病の予防又は治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5000000A (en) * 1988-08-31 1991-03-19 University Of Florida Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes
US6555371B1 (en) * 1997-07-09 2003-04-29 Seikagaku Kogyo Kabushiki Kaisha Sialyltransferase and DNA encoding the same
US6280989B1 (en) * 1999-06-17 2001-08-28 Dmitri Kapitonov Sialyltransferases
EP3604537B1 (en) * 2003-06-13 2021-12-08 Alnylam Europe AG Double-stranded ribonucleic acid with increased effectiveness in an organism

Also Published As

Publication number Publication date
JP4921357B2 (ja) 2012-04-25
WO2005108600A1 (en) 2005-11-17
US20070224200A1 (en) 2007-09-27
KR20070007908A (ko) 2007-01-16
RU2006143156A (ru) 2008-06-20
ATE529531T1 (de) 2011-11-15
AU2005240714A1 (en) 2005-11-17
AU2005240714B2 (en) 2011-07-07
MXPA06012690A (es) 2007-01-16
CA2565676C (en) 2013-08-13
EP1743033A1 (en) 2007-01-17
CA2565676A1 (en) 2005-11-17
JP2007536292A (ja) 2007-12-13
ES2375626T3 (es) 2012-03-02
EP1743033B1 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
BRPI0510697A (pt) gm3 sintase como um alvo terapêutico em complicações micro-vasculares da diabete
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
PH12015502362A1 (en) Certain chemical entities, compositions and methods
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
TW200745109A (en) Pyrrolo-pyridine kinase modulators
NO20084712L (no) Nye farmasoytiske forbindelser
EP2494059A4 (en) USE OF METHYSULFONYLMETHANE (MSM) FOR MODULATION OF MICROBIAL ACTIVITY
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
NO20092569L (no) Inhibitorer av Akt-aktivitet
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UA95244C2 (ru) Соединения и способ модулирования активности киназ, и показания для их применения
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TNSN08400A1 (en) Organic compounds and their uses
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2009158031A3 (en) Methods and compositions for therapeutic treatment
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]